Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 21 of 21 results for dapagliflozin type 1 diabetes

  1. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

  2. Dapagliflozin for treating chronic kidney disease (TA1075)

    Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.

  3. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  4. Empagliflozin for treating chronic kidney disease (TA942)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.

  5. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  6. Biggest shake-up in type 2 diabetes care in a decade announced

    Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.